197 related articles for article (PubMed ID: 30965052)
41. Utilization and Toxicity of Alternative Delivery Methods of Adjuvant Chemotherapy for Ovarian Cancer.
Wright JD; Hou JY; Burke WM; Tergas AI; Chen L; Hu JC; Ananth CV; Neugut AI; Hershman DL
Obstet Gynecol; 2016 Jun; 127(6):985-991. PubMed ID: 27159764
[TBL] [Abstract][Full Text] [Related]
42. Out-of-Pocket Spending for Hospitalizations Among Nonelderly Adults.
Adrion ER; Ryan AM; Seltzer AC; Chen LM; Ayanian JZ; Nallamothu BK
JAMA Intern Med; 2016 Sep; 176(9):1325-32. PubMed ID: 27367932
[TBL] [Abstract][Full Text] [Related]
43. Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?
Sioulas VD; Schiavone MB; Kadouri D; Zivanovic O; Roche KL; O'Cearbhaill R; Abu-Rustum NR; Levine DA; Sonoda Y; Gardner GJ; Leitao MM; Chi DS
Gynecol Oncol; 2017 Apr; 145(1):15-20. PubMed ID: 28238354
[TBL] [Abstract][Full Text] [Related]
44. Survival After Primary Debulking Surgery Compared With Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A National Cancer Database Study.
Seagle BL; Graves S; Strohl AE; Shahabi S
Int J Gynecol Cancer; 2017 Oct; 27(8):1610-1618. PubMed ID: 28763362
[TBL] [Abstract][Full Text] [Related]
45. Chemotherapy Use, End-of-Life Care, and Costs of Care Among Patients Diagnosed With Stage IV Pancreatic Cancer.
Bao Y; Maciejewski RC; Garrido MM; Shah MA; Maciejewski PK; Prigerson HG
J Pain Symptom Manage; 2018 Apr; 55(4):1113-1121.e3. PubMed ID: 29241809
[TBL] [Abstract][Full Text] [Related]
46. First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis.
Neyt M; Vlayen J; Devriese S; Camberlin C
PLoS One; 2018; 13(4):e0195134. PubMed ID: 29630612
[TBL] [Abstract][Full Text] [Related]
47. Patterns of treatment, healthcare utilization and costs by lines of therapy in metastatic breast cancer in a large insured US population.
Ray S; Bonthapally V; McMorrow D; Bonafede M; Landsman-Blumberg P
J Comp Eff Res; 2013 Mar; 2(2):195-206. PubMed ID: 24236561
[TBL] [Abstract][Full Text] [Related]
48. A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy.
May T; Comeau R; Sun P; Kotsopoulos J; Narod SA; Rosen B; Ghatage P
Int J Gynecol Cancer; 2017 May; 27(4):668-674. PubMed ID: 28441250
[TBL] [Abstract][Full Text] [Related]
49. High-deductible health plans and costs and utilization of maternity care.
Kozhimannil KB; Huskamp HA; Graves AJ; Soumerai SB; Ross-Degnan D; Wharam JF
Am J Manag Care; 2011 Jan; 17(1):e17-25. PubMed ID: 21485419
[TBL] [Abstract][Full Text] [Related]
50. BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy.
Gorodnova T; Sokolenko A; Ni V; Ivantsov A; Kotiv K; Petrik S; Amelina I; Berlev I; Imyanitov E
Int J Gynecol Cancer; 2019 May; 29(4):779-786. PubMed ID: 30839285
[TBL] [Abstract][Full Text] [Related]
51. Evaluating a novel online behavioural intervention to encourage cost-conscious strategies among US adults with chronic conditions who are enrolled in a high-deductible health plan: a proof-of-concept pilot study.
Peirce A; Lin YJ; Fagerlin A; Heisler M; Levy H; Kullgren J
BMJ Open; 2024 May; 14(5):e076852. PubMed ID: 38772581
[TBL] [Abstract][Full Text] [Related]
52. Total and out-of-pocket costs for PARP inhibitors among insured ovarian cancer patients.
Liang MI; Chen L; Hershman DL; Hillyer GC; Huh WK; Guyton A; Wright JD
Gynecol Oncol; 2021 Mar; 160(3):793-799. PubMed ID: 33375989
[TBL] [Abstract][Full Text] [Related]
53. Cost-Sharing and Out-of-Pocket Cost for Women Who Received MRI for Breast Cancer Screening.
Pan IW; Oeffinger KC; Shih YT
J Natl Cancer Inst; 2022 Feb; 114(2):254-262. PubMed ID: 34320199
[TBL] [Abstract][Full Text] [Related]
54. Costs of treatment for elderly women with advanced ovarian cancer in a Medicare population.
Forde GK; Chang J; Ziogas A; Tewari K; Bristow RE
Gynecol Oncol; 2015 Jun; 137(3):479-84. PubMed ID: 25866323
[TBL] [Abstract][Full Text] [Related]
55. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
[TBL] [Abstract][Full Text] [Related]
56. Patient-Provider Discussion About Cancer Treatment Costs and Out-of-Pocket Spending: Implications for Shared Decision Making in Cancer Care.
Hong YR; Salloum RG; Yadav S; Smith G; Mainous AG
Value Health; 2020 Dec; 23(12):1592-1598. PubMed ID: 33248514
[TBL] [Abstract][Full Text] [Related]
57. Comparing Health Care Financial Burden With an Alternative Measure of Unaffordability.
Kielb ES; Rhyan CN; Lee JA
Inquiry; 2017 Jan; 54():46958017732960. PubMed ID: 28975850
[TBL] [Abstract][Full Text] [Related]
58. Association of High-Deductible Health Plans With Health Care Use and Costs for Patients With Cardiovascular Disease.
Gupta R; Yang L; Lewey J; Navathe AS; Groeneveld PW; Khatana SAM
J Am Heart Assoc; 2023 Oct; 12(19):e030730. PubMed ID: 37750565
[TBL] [Abstract][Full Text] [Related]
59. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
60. Safety and efficacy of neoadjuvant chemotherapy with bevacizumab in advanced-stage peritoneal/ovarian cancer patients.
Kusunoki S; Terao Y; Hirayama T; Fujino K; Ujihira T; Ota T; Takeda S
Taiwan J Obstet Gynecol; 2018 Oct; 57(5):650-653. PubMed ID: 30342644
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
